| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Douglas Cines | Q16204220 |
| P2093 | author name string | Carlos H Villa | |
| Don L Siegel | |||
| Vladimir Muzykantov | |||
| P2860 | cites work | Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier | Q26801300 |
| Red blood cell deformability during storage: towards functional proteomics and metabolomics in the Blood Bank | Q27007466 | ||
| Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial | Q27498979 | ||
| Role of CD47 as a marker of self on red blood cells | Q28138449 | ||
| Cell-based drug delivery | Q28257039 | ||
| The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy | Q28257521 | ||
| p-Diazobenzoyl biocytin--a new biotinylating reagent for the labeling of tyrosines and histidines in proteins | Q28303880 | ||
| The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage | Q28588149 | ||
| Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia | Q30306672 | ||
| Modelling the structure of the red cell membrane | Q30401348 | ||
| Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor | Q30408386 | ||
| Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis | Q30444430 | ||
| Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment | Q30445571 | ||
| Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. | Q30465415 | ||
| Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys | Q30466269 | ||
| Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. | Q30469896 | ||
| Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model | Q30471329 | ||
| Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model. | Q30472083 | ||
| Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent | Q30500397 | ||
| Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis | Q30514795 | ||
| Partial tolerance of autoreactive B and T cells to erythrocyte-specific self-antigens in mice | Q30537231 | ||
| Effects of red-cell storage duration on patients undergoing cardiac surgery | Q30853037 | ||
| Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. | Q33421373 | ||
| Improving protein pharmacokinetics by engineering erythrocyte affinity | Q33689815 | ||
| Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis | Q33714889 | ||
| Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the n | Q33734359 | ||
| Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes | Q33925997 | ||
| Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation | Q33944248 | ||
| Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. | Q34028841 | ||
| Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK. | Q34167946 | ||
| Proof of principle for transfusion of in vitro-generated red blood cells. | Q34212764 | ||
| Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells | Q34228733 | ||
| Long-term physiological effects of enhanced O2 release by inositol hexaphosphate-loaded erythrocytes | Q34350601 | ||
| Ligation of complement receptor 1 increases erythrocyte membrane deformability | Q34541629 | ||
| Antibody-drug conjugates: targeted drug delivery for cancer | Q34621670 | ||
| Erythrocyte membrane rigidity induced by glycophorin A-ligand interaction. Evidence for a ligand-induced association between glycophorin A and skeletal proteins | Q34630365 | ||
| Enzyme loading of erythrocytes | Q34734234 | ||
| Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models. | Q34792041 | ||
| Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation | Q35227861 | ||
| Established and theoretical factors to consider in assessing the red cell storage lesion | Q35252618 | ||
| Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions | Q35597837 | ||
| Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. | Q39315460 | ||
| Nanoparticle Attachment to Erythrocyte Via the Glycophorin A Targeted ERY1 Ligand Enhances Binding without Impacting Cellular Function | Q40059157 | ||
| A soluble recombinant multimeric anti-Rh(D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes. | Q40781597 | ||
| Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens | Q40933700 | ||
| The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics | Q41302329 | ||
| Construction and characterization of adriamycin-loaded canine red blood cells as a potential slow delivery system | Q41831177 | ||
| Avidin acylation prevents the complement-dependent lysis of avidin-carrying erythrocytes | Q41866358 | ||
| Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile | Q42028534 | ||
| Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement | Q42090846 | ||
| Technetium-labeled erythrocyte scintigraphy in acute gastrointestinal bleeding | Q43501786 | ||
| Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. | Q43627843 | ||
| Harmful effects of transfusion of older stored red blood cells: iron and inflammation | Q44187180 | ||
| Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis | Q44298398 | ||
| Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy | Q45862908 | ||
| Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement | Q45897609 | ||
| Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia | Q46060729 | ||
| Immunological Response to L-Asparaginase Loaded into Red Blood Cells | Q46197556 | ||
| Erythrocyte vesiculation: a self-protective mechanism? | Q46639294 | ||
| Preparation and characterization of 'heparinocytes': erythrocytes with covalently bound low molecular weight heparin | Q47245873 | ||
| Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. | Q47733979 | ||
| Characterization of heme as activator of Toll-like receptor 4. | Q47787071 | ||
| Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium | Q47856316 | ||
| Dual role of erythrocyte complement receptor type 1 in immune complex-mediated macrophage stimulation: implications for the pathogenesis of Plasmodium falciparum malaria | Q47992165 | ||
| Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation | Q50263128 | ||
| Influence of the glycocalyx and plasma membrane composition on amphiphilic gold nanoparticle association with erythrocytes. | Q50442759 | ||
| Resistance of a subset of red blood cells to clearance by antibodies in a mouse model of incompatible transfusion. | Q50502505 | ||
| l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. | Q50545214 | ||
| In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy. | Q50584120 | ||
| Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. | Q50649233 | ||
| In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. | Q50748912 | ||
| Blood clearance and activity of erythrocyte-coupled fibrinolytics. | Q50782336 | ||
| A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. | Q51979076 | ||
| The mouse immune response to carrier erythrocyte entrapped antigens. | Q52015425 | ||
| Comparison of modified technetium-99m albumin and technetium-99m red blood cells for equilibrium ventriculography. | Q52899064 | ||
| Contribution of erythrocytes to thrombin generation in whole blood. | Q53891649 | ||
| Avidin attachment to red blood cells via a phospholipid derivative of biotin provides complement-resistant immunoerythrocytes. | Q54247649 | ||
| Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages | Q54981114 | ||
| Inhibition of malarial parasite invasion by monoclonal antibodies against glycophorin A correlates with reduction in red cell membrane deformability | Q56380169 | ||
| A study of in vivo immune complex formation and clearance in man | Q57089753 | ||
| Tolerance Evaluation of L -asparaginase loaded in red blood cells | Q57571636 | ||
| In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium | Q61651704 | ||
| In vivo survival and organ uptake of loaded carrier rat erythrocytes | Q61661280 | ||
| Erythrocytes as a controlled drug delivery system: Clinical evidences | Q62572587 | ||
| A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1) | Q63977232 | ||
| Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation | Q67478650 | ||
| Fast lysis by complement and uptake by liver of avidin-carrying biotinylated erythrocytes | Q67577403 | ||
| Red blood cells as an antigen-delivery system | Q67957653 | ||
| In vitro targeting of erythrocytes to cytotoxic T-cells by coupling of Thy-1.2 monoclonal antibody | Q68126098 | ||
| Selective labeling of sulfhydryls and disulfides on blot transfers using avidin-biotin technology: studies on purified proteins and erythrocyte membranes | Q68993206 | ||
| Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot | Q69637205 | ||
| Streptavidin-induced lysis of homologous biotinylated erythrocytes. Evidence against the key role of the avidin charge in complement activation via the alternative pathway | Q70128283 | ||
| Red blood cell deformability influences platelets--vessel wall interaction in flowing blood | Q70668401 | ||
| A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion | Q70862056 | ||
| Target-sensitive immunoerythrocytes: interaction of biotinylated red blood cells with immobilized avidin induces their lysis by complement | Q71005190 | ||
| Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells | Q71256026 | ||
| Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats | Q71394640 | ||
| Heterogeneity of hypotonically loaded rat erythrocyte populations as detected by counter-current distribution in aqueous polymer two-phase systems | Q71791345 | ||
| Attachment of Biotinylated Antibody to Red Blood Cells: Antigen-Binding Capacity of Immunoerythrocytes and Their Susceptibility to Lysis by Complement | Q72106911 | ||
| Naturally occurring human anti-band 3 autoantibodies accelerate clearance of erythrocytes in guinea pigs | Q72126163 | ||
| Perturbation of red blood cell membrane rigidity by extracellular ligands | Q72344954 | ||
| Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes | Q73621576 | ||
| Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease | Q73691992 | ||
| In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase | Q73968435 | ||
| RBC T activation and hemolysis: implications for pediatric transfusion management | Q74105668 | ||
| ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement | Q75270684 | ||
| Erythrocytes as carriers for drugs: the transition from the laboratory to the clinic is approaching | Q83197975 | ||
| Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. | Q35776447 | ||
| Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease | Q35813199 | ||
| Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature | Q35848131 | ||
| Directed targeting of immunoerythrocytes provides local protection of endothelial cells from damage by hydrogen peroxide | Q35856035 | ||
| Ligation of Glycophorin A Generates Reactive Oxygen Species Leading to Decreased Red Blood Cell Function | Q35897675 | ||
| Time to revisit red blood cell additive solutions and storage conditions: a role for "omics" analyses | Q36162760 | ||
| Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase | Q36284750 | ||
| Erythrocyte-based drug delivery. | Q36316729 | ||
| Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation | Q36370881 | ||
| Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes | Q36381471 | ||
| International seminar on the red blood cells as vehicles for drugs. | Q36382149 | ||
| Engineering antigens for in situ erythrocyte binding induces T-cell deletion | Q36512070 | ||
| Effects of Aged Stored Autologous Red Blood Cells on Human Endothelial Function | Q36516529 | ||
| Applications of carrier erythrocytes in delivery of biopharmaceuticals | Q36725488 | ||
| Red Cell-Mediated Therapy: Opportunities and Challenges | Q36870018 | ||
| Modifying the red cell surface: towards an ABO-universal blood supply. | Q36985969 | ||
| Drug loaded erythrocytes: as novel drug delivery system | Q37066286 | ||
| A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. | Q37151690 | ||
| Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator | Q37263891 | ||
| Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation | Q37285884 | ||
| Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro | Q37312867 | ||
| Carrier-directed targeting of liposomes and erythrocytes to denuded areas of vessel wall. | Q37397955 | ||
| Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo | Q37641880 | ||
| Fibrinogen and red blood cells in venous thrombosis | Q37730948 | ||
| Immune hemolytic anemia caused by drugs | Q38002535 | ||
| Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations | Q38017396 | ||
| Survival of red blood cells after transfusion: processes and consequences | Q38175975 | ||
| Effect of Transfusion of Red Blood Cells With Longer vs Shorter Storage Duration on Elevated Blood Lactate Levels in Children With Severe Anemia: The TOTAL Randomized Clinical Trial | Q38398840 | ||
| Age of transfused blood in critically ill adults | Q38427195 | ||
| Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial | Q38463070 | ||
| Intracellular delivery of nanocarriers and targeting to subcellular organelles | Q38584491 | ||
| PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs | Q38730623 | ||
| Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems | Q38760096 | ||
| Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells | Q38865261 | ||
| P433 | issue | 1 | |
| P921 | main subject | drug delivery | Q1392806 |
| P304 | page(s) | 26-35 | |
| P577 | publication date | 2016-08-17 | |
| P1433 | published in | Transfusion Medicine Reviews | Q15758511 |
| P1476 | title | Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond | |
| P478 | volume | 31 |
| Q90207123 | A Review of Controlled Drug Delivery Systems Based on Cells and Cell Membranes |
| Q91811850 | Advances on Non-Genetic Cell Membrane Engineering for Biomedical Applications |
| Q87606536 | Biocompatible coupling of therapeutic fusion proteins to human erythrocytes |
| Q39210548 | Biomimetic and bioinspired nanoparticles for targeted drug delivery |
| Q47295354 | Cell-Based Drug Delivery and Use of Nano-and Microcarriers for Cell Functionalization. |
| Q39011174 | Drug delivery by erythrocytes: "Primum non nocere". |
| Q47859467 | Engineered red blood cells as therapeutic agents |
| Q38642538 | Erythrocyte-based drug delivery in Transfusion Medicine: Wandering questions seeking answers |
| Q37707194 | Formulation and Drug Loading Features of Nano-Erythrocytes. |
| Q89910045 | Recent strategies on targeted delivery of thrombolytics |
| Q47656459 | Simulation of the osmosis-based drug encapsulation in erythrocytes |
Search more.